bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1712762
Sentiment: neutral
Topics: corporate-filing, research, sec-filing
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on 12/19/25, confirming its research focus and Texas HQ.
AI Summary
On December 19, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates that the company is involved in commercial physical and biological research, specifically within industrial applications and services. The report details the company's incorporation in Delaware and its principal executive offices located in San Antonio, Texas.
Why It Matters
This filing provides an update on bioAffinity Technologies, Inc.'s corporate status and business activities, which is important for investors tracking the company's operations and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine corporate filing (8-K) that does not disclose new material financial events or significant business changes.
Key Numbers
- 001-41463 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5211056 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- December 19, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
- 8731 (sic_code) — Standard Industrial Classification
FAQ
What is the primary business of bioAffinity Technologies, Inc. according to this filing?
The filing indicates the company is involved in SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731], specifically within industrial applications and services.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 19, 2025.
In which state was bioAffinity Technologies, Inc. incorporated?
The company was incorporated in Delaware.
What is the physical address of bioAffinity Technologies, Inc.'s principal executive offices?
The principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the SEC file number for bioAffinity Technologies, Inc.?
The SEC file number is 001-41463.
Filing Stats: 615 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-12-19 17:00:33
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-25-028584.txt ( ) — 247KB
- biaf-20251219.xsd (EX-101.SCH) — 4KB
- biaf-20251219_def.xml (EX-101.DEF) — 26KB
- biaf-20251219_lab.xml (EX-101.LAB) — 36KB
- biaf-20251219_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-